brexucabtagene autoleucel
The firm reported strong revenue increases for its antibody-drug conjugate Trodelvy and its cell therapies Yescarta and Tecartus, offsetting losses outside oncology.
Gilead Sciences More Than Doubles Q1 Trodelvy Sales
The firm reported strong growth in revenues from its oncology segment, driven by the antibody-drug conjugate Trodelvy and CAR T-cell therapies Yescarta and Tecartus.
Gilead Sciences Q4 Cell Therapy Sales Increase 47 Percent
The firm's overall Q4 revenues decreased 2 percent year over year, but growth in the oncology segment remained strong.